UEG week virtual 2021

Is STRIDE II already history?

Where is the future in IBD treatment? P19, JAKi, S1P?

How to significantly reduce the arterial vascular risk in IBD treatment (with anti-TNF and thiopurine)

What's the right target? JAK1 or JAK3 or TYK2?

Discontinuation strategies: Data hint towards continuing Infliximab in CD patients with remission

IL-23: Risankizumab - effective maintenance, long carry over of clinical remission.

A panoramic view of UEG and IBD from Spain

Single JAK targeting: JAK1 vs. JAK3

STRIDE 2.0 - Treatment goals in IBD: Patient Perspectives, Transmural healing

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

Side Effects - Biologicals: News from UEGw

Do we need H2H trials? We need new endpoints, regaining QoL, there is still more to explore!

What's the right target? JAK1 or JAK3 or TYK2?

Treatment targets: The impact of STRIDE II on our clinical practice. New targets needed!

Targeting S1P: effective, well tolerated, soon to be approved. Affordable?

Do we need IL-23 blockade? Are all inhibitors the same?

Review JAK1 Inhibition: great speed of action, execellent maintenance, well tolerated.

What do drug levels and antibody levels tell us?

Single JAK targeting: JAK1 vs. JAK3

IL-23: Risankizumab - effective maintenance, long carry over of clinical remission.

S1P targeting: very immediate effficacy and good safety profile

Upadacitinib with rapid and effective control of symptoms and reduction of inflammation markers

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

Dose escalation strategies to increase the efficacy of Ustekinumab

Tofacitinib numerically increases Herp Zoster risk however without high severity. More data needed.

Risankizumab: Effektive Erhaltung mit Langzeiteffekt

Dose escalation strategies to increase the efficacy of Ustekinumab

JAK1 vs. JAK3 - was ist effektiver?

S1P Rezeptor Agonisten mit unmittelbarer Effektivität und guter Verträglichkeit

Neue JAK-Therapieoptionen vor der Zulassung. Es wird komplexer!

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

Immunosuppression and COVID: vaccination is effective, booster required, do not discontinue IMM and/or biologics

Side Effects - Biologicals: News from UEGw

Side Effects - Oral Therapies: News from UEGw

Safety of Ustekinumab in elderly patients - no increased risk

How to significantly reduce the arterial vascular risk in IBD treatment (with anti-TNF and thiopurine)

Protein profiling as efficacy predictor of infliximab treatment

Protein profiling as efficacy predictor of infliximab treatment

Comment réduire le risque cardio-vasculaire associé aux MICI

IBD w wieku podeszłym - czy można bezpiecznie stosować ustekinumab?

What ist the most exciting new drug on the horizon? (UEGw and beyond)

Is STRIDE II already history?

Disease Clearance in UC: How can we translate this into clinical practice? The importance of histologic healing.

Disease clearance? Treat to target still correct?

Microbiome, nutrition and life style: The effect on disease outcome, consider local dietary options and remember diversity

PK SEAVUE Study: high proportion of patients with anti-drug antibodies does not affect efficacy

SEAVUE PK update: Immunogenicity of Ustekinumab vs Adalimumab

Risankizumab: 12 weeks induction in patients wo initial response can recapture >60%

Discontinuation strategies: Data hint towards continuing Infliximab in CD patients with remission

Do not stop infliximab in patients in complete remission

Czy warto kończyć terapię IFX w przypadku głębokiej remisji choroby Crohna?

Ustekinumab e Adalimumab: farmacocinetica e immunogenicità a confronto. Dati dallo studio SEAVUE.

Mieux vaut ne pas arrêter l’infliximab dans la maladie de Crohn

Disease Clearance the future therapeutic goal (endoscopic, histologic and clinical remission)

STRIDE 2.0 - Treatment goals in IBD: Patient Perspectives, Transmural healing

JAK inhibitors showing quick response in PRO improvement.

Therapieziele - STRIDE 2.0: Die Patientenperspektive, endoskopic remission, histologic remission clinical remission

Therapieziele: Disease Clearance bei der Colitis Ulcerosa

JAK inhibitors e rapidità nel miglioramento dei PROs: i nuovi steroidi?

Vedolizumab effective in resistant pouchitis

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

New treatment options: IL23 modulators Risankizumab and Guselkumab

Ritlecitinib & Brepocitinib good remission rates and good safety date

New treatment options about to be approved. Treatment choices will become more complex!

Ritlecitinib e Prebocitinib i nuovi arrivati nel mondo dei JAK inibitori

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

Neue Therapieoptionen: IL23 Modulation durch Risankizumab und Giselkumab

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib

Where is the future in IBD treatment? P19, JAKi, S1P?

A panoramic view of UEG and IBD from Spain

No assocation between COVID outcome and IBD therapy

Spanish IBD contributions to UEGW: more and more important

Aportación española a la UEGW en EII: más y mejor

No assocation between COVID outcome and IBD therapy

Un visión panorámica de la UEG y la EII desde España

UEG highlights: Vedolizumab in Chronic pouchitis;

Maintenance with Upadacitinib